

Joint Statement by JPMA, PhRMA and EFPIA

Background

- ❑ In order to protect people's health and maintain a vibrant society, an environment in which the public has access to innovative new drugs and vaccines is necessary.
- ❑ To this end, the attractiveness and competitive advantage of the Japanese market must be ensured, and R&D investments that attract innovation must be continued and developed.
- ❑ The following measures should be taken as the government's innovation strategy to achieve rapid access to medicines and economic growth.

Proposals for Honebuto Policy and Growth Strategy

- ❑ Adopt the construction of a "drug discovery innovation ecosystem" to deliver innovative new drugs as a national strategy and move forward with its implementation.
- ❑ Activate strategic dialogue between the public and private sectors and promote the establishment of KPIs and monitor progress of implementation of the MHLW "Pharmaceutical Industry Vision 2021".
- ❑ Develop and improve the R&D and regulatory environment to encourage continued investment in the Japanese market.
- ❑ Ensure a transparent, predictable and pro-innovation drug pricing system and maintain drug price levels for new drugs during the patent period.